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Epidemiologic studies have demonstrated that hypertension is usually accompanied
by major cardiovascular risk factors with less than 20% of hypertension occurring
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Purpose: The aim of this study was to determine whether retinol-binding protein 4
(RBP4), adiponectin and high molecular weight (HMW) adiponectin are associated
with insulin resistance (IR) and metabolic parameters in non-diabetic hypertensive
patients. Also, we sought to compare the predictive values of these adipocytokines
for IR in non-diabetic hypertensive patients. Materials and Methods: Analyses of
RBP4, adiponectin, and HMW adiponectin were performed on 308 non-diabetic
hypertensives (148 males, age 58 ± 10 years, 189 non-metabolic syndrome  and 119
metabolic syndrome). The homeostasis model assessment (HOMA) index for IR,
lipid profiles, and anthropometric measure-ments were assessed. Results: There was
no significant difference in RBP4 levels according to the presence of metabolic
syndrome, although adiponectin and HMW adiponectin were significantly lower in
metabolic syndrome. Correlation analysis of log RBP4 with IR and metabolic
indices revealed that there was no significant correlation of RBP4 with waist
circumference (r = 0.056, p = 0.324), HDL cholesterol (r = 0.005, p = 0.934),
ApoB/ApoAI ratio (r = 0.066, p = 0.270), and the HOMA index (r = 0.017, p =
0.756). However, adiponectin and HMW adiponectin showed significant
correlations with the HOMA index (r = - 0.247, p< 0.001; r = - 0.296, p< 0.001) and
metabolic parameters. With IR defined as HOMA index ≥ 2.5, HMW adiponectin
did not demonstrate a superior predictive value for IR compared to adiponectin
(AUC = 0.680 vs. 0.648, p = 0.083). The predictive value of RBP4 for IR was
minimal (AUC = 0.534). Conclusion: RBP4 was not associated with IR or
metabolic indices and the predictive value for IR was minimal in hypertensives.
HMW adiponectin didn’t have a superior predictive value for IR compared to
adiponectin. Therefore, we can suggest that RBP4 and HMW adiponectin don’t have
more additive information than adiponectin in non-diabetic hypertensives.
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INTRODUCTIONas an isolated manifestation.
1-3 The risk of cardiovascular
events in hypertensive patients increases in proportion to
the burden of associated risk factors.
1,4 Adipocytokines may
have a significant role in the manifestation of risk factors
in hypertensive patients. Of the studies on adipocytokines,
adiponectin is the most abundant adipocytokine in human
circulation and is known to be decreased in patients with
hypertension.
5,6 In human cross-sectional studies, plasma
adiponectin levels are negatively correlated with obesity
and waist-hip ratio, diabetic dyslipidemia, insulin resis-
tance (IR), and cardiovascular disease.
7,8 Therefore, the
level of plasma adiponectin may be an important determi-
nant of associated cardiovascular risk factors in hyperten-
sion as well. Recent studies have demonstrated the possible
importance of novel adipocytokines, such as retinol-
binding protein 4 (RBP4) and high molecular weight
(HMW) adiponectin, as a mediator for IR.
9-12 However,
some studies have reported contradictory findings regar-
ding the association of RBP4 with IR.
13,14 The added pre-
dictive value of HMW adiponectin compared to conven-
tional adiponectin also needs further validation; therefore,
in this study, we sought to determine the association bet-
ween RBP4, adiponectin, and HMW adiponectin with IR,
and metabolic cardiovascular risk factors in hypertensive
subjects.  
Study subjects
This was a cross sectional analysis of 308 non-diabetic
patients with hypertension. All subjects were enrolled in
the Seoul Metabolic Syndrome Research Initiatives, a
study sponsored by the city of Seoul to develop a pros-
pective cohort for hypertension and metabolic syndrome.
We enrolled non-diabetic treated hypertensive patients
with either a documented systolic blood pressure greater
than 140 mmHg and/or diastolic blood pressure greater
than 90 mmHg taken over three different visits after at
least 5 minutes rest in a sitting position prior to the com-
mencement of a blood pressure medication regimen or
patients currently taking antihypertensive medications for
treatment of hypertension at the time of enrollment.
Patients with the following conditions were excluded
from the study: Those with a significant history of
valvular heart disease, systemic disease and systemic
inflammatory disease; congestive heart failure; and serum
creatinine levels greater than 1.4 mg/dL. This study was
approved by the institutional ethics committee and the
procedures were followed in accordance with institutional
guidelines. All of the patients gave written informed con-
sent prior to the study.
Anthropometric and blood pressure measurements
Body weight and height measurements were taken in the
morning while subjects were unclothed and without shoes.
Body mass index (BMI) was calculated as body weight in
kilograms per height
2 (m
2). Waist circumference was taken
with a tape measure horizontally at the umbilicus while
subjects were in the standing position after normal expi-
ration. Blood pressure was measured from the dominant
arm of seated patients with a sphygmomanometer after 5
minutes of rest in sitting position. 
Definition of metabolic syndrome
Metabolic syndrome was diagnosed based on the Asian-
modified NCEP criteria
15 if 3 or more of the following con-
ditions were present: high blood pressure (systolic and/or
diastolic blood pressures ≥ 130/85 mmHg or patients
receiving anti-hypertensive drugs), hyperglycemia (fasting
plasma glucose ≥ 110 mg/dL or patients receiving oral
hypoglycemic agents), hypertriglyceridemia (fasting
plasma triglycerides ≥ 150 mg/dL), low HDL cholesterol
(fasting HDL cholesterol < 40 mg/dL for men and < 50
mg/dL for women), or central obesity (waist circumference
of  ≥ 90 cm for men and ≥ 80 cm for women). IR was de-
fined as homeostasis model assessment (HOMA) index of
≥ 2.5 according to the Japanese guideline for the treatment
of diabetes.
12
Biochemical analysis
Venous blood specimens were collected in EDTA-treated
and plain tubes after a 12 h fast. The tubes were imme-
diately placed on ice until they were transported to the
laboratory (within 1-3 h) and stored at -70˚C until analysis. 
Blood chemistry, including fasting glucose, blood urea
nitrogen, creatinine, uric acid, total cholesterol, triglyceride,
HDL cholesterol, LDL cholesterol, and fasting serum
insulin, were assessed. Fasting serum insulin levels were
measured using an immunoradiometric assay and a gamma
counter (Hewlett Packard, Meriden, Connecticut, USA). IR
was measured using the homeostasis model assessment of
the IR index (HOMA index) by the following formula:
HOMA index = [fasting insulin (µU/mL)×fasting glyce-
mia (mmol/L)] / 22.5.
Apolipoprotein B and apolipoprotein A assays were
measured by immunoturbidimetry (Roche Diagnostics,
Basel, Switzerland) as described previously.
16,17
Plasma adiponectin was measured using a radioimmu-
noassay (LINCO, St. Charles, Missouri, USA). Plasma
RBP4 was measured using ELISA (Immunodiagnostik,
Bensheim, Germany). Plasma HMW adiponectin was
measured using ELISA (LINCO, St. Charles, Missouri,
USA). Plasma HMW adiponectin/total plasma adiponectin
ratio was calculated as the ratio of HMW adiponectin/
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MATERIALS AND METHODS (HMW adiponectin + low molecular weight adiponectin)
based upon a previous study by Pajvani, et al.
18
Statistical analysis
The study population was divided according to the presence
or absence of metabolic syndrome. Continuous variables are
presented as mean ± standard deviation and categorical
variables as absolute and relative frequencies (%). Con-
tinuous variables were compared using the student’s t-test.
Categorical variables were compared using chi-square test.
Simple correlation analyses were performed to determine
the association between RBP4, adiponectin, HMW adipo-
nectin, variables of IR, and metabolic cardiovascular risk
factors. To normalize the distribution, a natural logarithmic
transformation was applied to variables that were not in the
normal distribution. To determine the independent associa-
tion of the adipocytokines with cardiovascular risk factors,
multiple linear regression was performed with age, the
HOMA index, triglyceride levels, HDL cholesterol, and the
ApoB/ApoAI ratio as dependent variables. The predictive
power of each adipocytokines for identifying patients with
IR was analyzed using the receiver operating characteristic
(ROC) curve analysis. Statistical analyses were done using
SPSS statistical software package (version 13.0, SPSS Inc.,
Chicago, IL, USA). Comparisons of the ROC curves were
performed using MedCalc statistical software package
Adipocytokines and Insulin Resistance
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Table 1.Baseline Clinical Characteristics According to Presence of Metabolic Syndrome
Non-metabolic Metabolic
pvalue*
Syndrome  (n = 189) Syndrome (n = 119)
Age (yr) 58 ± 10 57 ± 10 0.458
Gender (male : female) 108 : 81 40 : 79 < 0.001
Height (cm) 162.4 ± 7.7 160.4 ± 8.4 0.039
Weight (kg) 65.1 ± 10.1 67.3 ± 11.3 0.074
Waist (cm) 86.6 ± 7.7 90.8 ± 8.4 < 0.001
BMI (kg/m
2) 24.6 ± 2.9 26.1 ± 3.0 < 0.001
Systolic BP (mmHg) 123.8  ± 13.5 125.9  ± 14.1 0.197
Diastolic BP (mmHg) 78.8  ± 9.6 79.7  ± 8.2 0.377
Fasting glucose (mg/dL) 88.2 ± 9.9 93.6 ± 18.7 0.001
Fasting insulin (µU/mL) 8.9 ± 4.2 11.4 ± 5.0 < 0.001
HOMA index 1.96 ± 1.03 2.64 ± 1.38 < 0.001
Total cholesterol (mg/dL) 178.3 ± 36.6 182.6 ± 37.9 0.325
LDL cholesterol (mg/dL) 100.2 ± 31.3 100.3 ± 34.5 0.979
HDL cholesterol (mg/dL) 56.1 ± 11.6 44.8 ± 10.1 < 0.001
Triglyceride (mg/dL) 105.2 ± 34.2 175.9 ± 66.5 < 0.001
Apolipoprotein B (mg/dL)  74.9 ± 19.0 86.6 ± 22.8 < 0.001
Apolipoprotein AI (mg/dL) 132.4 ± 29.3 122.3 ± 27.1 0.003
ApoB ApoAI ratio 0.56 ± 0.16 0.70 ± 0.20 < 0.001
Uric acid (mg/dL) 5.1 ± 1.3 5.2 ± 1.2 0.560
Serum creatinine (mg/dL) 0.8  ± 0.2 0.7 ± 0.2 0.269
hs CRP (mg/L) 1.42 ± 4.48  1.42 ± 1.96 0.996
Medications
ACE inhibitors, n (%) 24 (12.7) 10 (8.4) 0.242
ARB, n (%) 68 (36.0) 44 (37.0) 0.860
Beta blockers, n (%) 76 (40.2) 48 (40.3) 0.983
CCB, n (%) 123 (65.1) 72 (60.5) 0.417
Diuretics, n (%) 34 (18.0) 25 (21.0) 0.553
Alpha blockers, n (%) 5 (2.6) 3 (2.5) 0.947
Statins, n (%) 52 (27.5) 39 (32.8) 0.325
BMI, body mass index; BP, blood pressure; HOMA, homeostasis model assessment; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; Apo, apolipoprotein; CRP, c-reactive protein; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CCB,
calcium channel blocker.
*p< 0.05 is considered significant.(version 9.3.3.0, Mariakerke, Belgium). A p-value of < 0.05
was considered to be statistically significant.
Clinical characteristics 
The age of the study population was 58 ± 10 years. There
were 148 males and 160 females analyzed in this study.
Among the 308 patients, 119 patients met the NCEP criteria
for metabolic syndrome. There were no significant dif-
ference in blood pressure, total cholesterol, LDL cholesterol,
serum creatinine, and hsCRP among the two groups but
females were predominant in the group with metabolic
syndrome. The metabolic parameters were significantly
different between the two groups because of the study
design (Table 1). 
Most of the subjects enrolled in the study were well con-
trolled hypertensive patients taking antihypertensive medi-
cations at the time of enrollment. The relatively low value
of LDL cholesterol in this study population may be ex-
plained as 29.5% of the study population was taking statins
at the time of enrollment (Table 1). The total cholesterol and
LDL cholesterol in non-metabolic syndrome without statins
were 187.6 ± 33.0 mg/dL and 108.4 ± 28.2 mg/dL and with
statins were 153.8 ± 34.7 mg/dL and 78.8  ± 28.7 mg/dL.
Those with metabolic syndrome without statins were 188.2
± 35.4 mg/dL and 109.1 ± 30.9 mg/dL and with statins
were 171.2 ± 40.5 mg/dL and  82.9 ± 35.1 mg/dL.
Adipocytokines according to the presence of metabolic
syndrome
Because of gender differences in the level of adipocy-
tokines and gender distribution in the two groups, we
analyzed the adipocytokines in each gender. There was no
significant difference in RBP4 levels according to the
presence of metabolic syndrome in both genders, although
there were significantly lower levels of adiponectin and
HMW adiponctin in patients with metabolic syndrome.
The HMW/total adiponectin ratio was significantly lower,
especially in female patients with metabolic syndrome
(Table 2). 
Correlation of adipocytokines with insulin resistance
and cardiovascular risk factors
Correlation analysis of log transformed RBP4 with IR and
metabolic parameters revealed that there was no significant
correlation of RBP4 with waist circumference, HDL choles-
terol, ApoB/ApoAI ratio, and the HOMA index, although
RBP4 was correlated with triglycerides (r = 0.246, p <
0.001) and uric acid (r = 0.322, p < 0.001). There was also
no significant correlation of RBP4 with adiponectin and
HMW adiponectin (Fig. 1A).
The correlation analysis for adiponectin and HMW adi-
ponectin revealed a significant correlation with metatolic
parameters (Fig. 1B, C). There was a significant correlation
with adiponectin, but not HMW adiponectin with ApoB/
ApoAI ratio (r = - 0.133, p = 0.026, r = - 0.106, p = 0.076).
There was an excellent correlation between adiponectin
and HMW adiponectin (r = 0.863, p< 0.001).
Independent association of adiponectin, HMW adipo-
nectin, and HMW adiponectin/adiponectin ratio with
insulin resistance and cardiovascular risk factors
Adiponectin was independently associated with the HOMA
index (β = - 0.230, p < 0.001), HDL cholesterol (β = 0.304,
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RESULTS
Table 2. Plasma RBP4, Adiponectin, and HMW Adiponectin by Study Group and Gender
Non-metabolic Metabolic
pvalue*
Syndrome (n = 189) Syndrome (n = 119)
RBP4 (ug/mL) Total 34.8 ± 13.3 37.4 ± 14.5 0.114
Male (n = 148) 37.0 ± 13.3 41.8 ± 14.1 0.056
Female (n = 160) 31.9 ± 12.6 35.1 ± 14.3 0.131
Adiponectin Total 9.4 ± 5.5 8.5 ± 4.9 0.153
(ug/mL) Male (n = 148) 7.7 ± 4.5 6.2 ± 3.5 0.043
Female (n = 160) 11.8 ± 5.9 9.7 ± 5.0 0.019
HMW adiponectin  Total 2.6 ± 2.1 2.1 ± 1.7 0.025
(ug/mL) Male (n = 148) 1.9 ± 1.7 1.4 ± 1.3 0.085
Female (n = 160) 3.5 ± 2.2 2.5 ± 1.7 0.001
HMW/total  Total 0.25 ± 0.13 0.23 ± 0.11 0.155
adiponectin ratio Male (n = 148) 0.22 ± 0.12 0.20 ± 0.11 0.486
Female (n = 160) 0.30 ± 0.12 0.25 ± 0.11 0.007
RBP4, retinol-binding protein 4; HMW, high-molecular weight.
*p< 0.05 is considered significant.p < 0.001), and ApoB/ApoAI ratio (β = 0.117, p = 0.039)
when controlled for BMI, lipid profiles, and age. There
was no significant independent association with triglycerides
in this study. A similar finding was observed for HMW
adiponectin. A similar trend was observed in the HMW
adiponectin/total adiponectin ratio in the HOMA index and
HDL cholesterol but there was a weak correlation with
marginal significance (β = 0.099 , p = 0.072) between the
adiponectin ratio and ApoB/Apo AI ratio (Table 3).
Predictive value of adipocytokines for insulin 
resistance
The ROC curves were plotted for the predictive power of
adipocytokines for IR. The results showed that the area
under the curve of HMW adiponectin was slightly larger
than that of adiponectin without statistical significance
[0.680 (95% CI 0.611-0.748)] vs. [0.648 (95% CI 0.579-
0.716), p = 0.083] (Fig. 2A), suggesting that HMW adi-
ponectin  wasn’t superior for predicting IR than conventio-
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Fig. 1. Correlation of RBP4, adiponectin, and HMW adiponectin with metabolic parameters in hypertensive subjects. (A) Log RBP4, (B) Log adiponectin, (C) Log HMW
adiponectin. RBP4, retinol-binding protein 4; HMW, high-molecular weight.
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Table 3. Independent Association of Plasma Adiponectin, HMW Adiponectin, and HMW Adiponectin/total 
Adiponectin Ratio with Insulin Resistance and Cardiovascular Risk Factors
Dependent variable Independent variable Standardized coefficient pvalue*
Adiponectin
BMI 0.364 <  0.001
HOMA index 
Triglyceride 0.100 0.076
(R2 = 0.212)
Log adiponectin  - 0.230 < 0.001
HDL cholesterol 0.058 0.333
Age - 0.082 0.128
HOMA index 0.110 0.076
Triglyceride
Log adiponectin - 0.068 0.269
(R2 = 0.135)
Age - 0.015 0.796
BMI - 0.091 0.137
HDL cholesterol - 0.317 < 0.001
Triglyceride - 0.280 < 0.001
HDL cholesterol
Age - 0.048 0.366
(R2 = 0.235)
BMI - 0.211 < 0.001
Log adiponectin 0.304 < 0.001
HOMA index 0.057 0.333
Age - 0.037 0.465
BMI - 0.105 0.063
ApoB/Apo AI ratio Log adiponectin 0.117 0.039
(R2 = 0.364) HOMA index 0.021 0.710
HDL cholesterol - 0.547 < 0.001
Triglyceride 0.202 < 0.001
HMW adiponectin
BMI 0.359 < 0.001
HOMA index
Triglyceride 0.100 0.074
(R2 = 0.226)
Log HMW adiponectin - 0.265 < 0.001
HDL cholesterol 0.062 0.292
Age - 0.050 0.353
HOMA index 0.112 0.074
Triglyceride
Log HMW adiponectin - 0.054 0.389
(R2 = 0.133)
Age - 0.010 0.863
BMI - 0.094 0.126
HDL cholesterol - 0.324 < 0.001
Triglyceride - 0.290 < 0.001
HDL cholesterol
Age - 0.078 0.149
(R2 = 0.225)
BMI - 0.207 < 0.001
Log HMW adiponectin 0.290 < 0.001
HOMA index 0.063 0.292
Age - 0.054 0.297
BMI - 0.106 0.059
ApoB/Apo AI ratio Log HMW adiponectin 0.136 0.019
(R2 = 0.367) HOMA index 0.032 0.586
HDL cholesterol - 0.549 < 0.001
Triglyceride 0.202 < 0.001nal adiponectin. Also, there was no additive predictive
value of the HMW adiponectin/total adiponectin ratio for
predicting IR compared to adiponectin [0.652 (95% CI
0.583-0.722)] vs. [0.648 (95% CI 0.579-0.716), p = 0.734].
When a cutoff value of 7.0 ug/ml was used, plasma adipo-
nectin predicted the presence of IR with a sensitivity of
Adipocytokines and Insulin Resistance
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Fig. 2. ROC curves of adipocytokines for prediction of insulin resistance, defined as HOMA-IR index > 2.5 (n = 308), in hypertensive subjects. (A)
Plasma adiponectin and HMW adiponectin. (B) Plasma RBP4. AUC, area under curve; ROC, receiver operating characteristics; HOMA,
homeostasis model assessment; RBP4, retinol-binding protein 4.
Table 3. Continued
Dependent variable Independent variable Standardized coefficient pvalue*
HMW adiponectin/total adiponectin ratio
BMI 0.351 < 0.001
HOMA index Triglyceride 0.111 0.049
(R2 = 0.207) Log adiponectin ratio - 0.212 < 0.001
HDL cholesterol 0.023 0.693
Age - 0.049 0.378
HOMA index 0.122 0.049
Triglyceride Log adiponectin ratio - 0.021 0.730
(R2 = 0.131) Age - 0.014 0.808
BMI(kg/m
2) - 0.099 0.106
HDL cholesterol - 0.337 < 0.001
Triglyceride - 0.318 < 0.001
HDL cholesterol
Age - 0.072 0.200
(R2 = 0.180)
BMI - 0.197 0.001
Log adiponectin ratio 0.179 0.002
HOMA index 0.024 0.693
Age - 0.053 0.312
BMI - 0.096 0.088
ApoB/Apo AI ratio Log adiponectin ratio 0.099 0.072
(R2 = 0.361) HOMA index 0.014 0.812
HDL cholesterol - 0.526 < 0.001
Triglyceride 0.198 < 0.001
HMW, high-molecular weight; HOMA, homeostasis model assessment; BMI, body mass index.
*p< 0.05 is considered significant.
AB66.3% and specificity of 60.7%. The sensitivity and speci-
ficity of HMW adiponectin for predicting IR was 70.7%
and 61.8% at a cutoff value of 1.48 ug/mL, and the HMW
adiponectin/total adiponectin ratio diagnosed IR with a
sensitivity of 72.1% and specificity of 60.7% at a cutoff
level of 1.44.  Regarding RBP4, the area under the curve
was only 0.534 (95% CI 0.462-0.605) in this study (Fig. 2B).  
One of the key findings in this study was that plasma RBP4
was not associated with indices of metabolic syndrome,
such as waist circumference, HDL cholesterol, ApoB/
ApoAI ratio, and the HOMA index. However, there was a
significant correlation of RBP4 with serum triglycerides. 
RBP4 has been identified as an adipocytokine that is
increased in circulation in mouse models of obesity and
insulin resistance.
18 Furthermore, transgenic expression and
administration of RBP4 into mice induced insulin resistance
in this previous report.
19 However, some studies have
reported contradictory findings regarding the association of
RBP4 with IR.
13-14 So, the assessment of the importance of
RBP4 is needed in diverse groups. Our findings of this
study are in accordance with findings reported by Takas-
hima, et al.
19, which showed that serum RBP4 did not cor-
relate with fasting blood glucose, HDL cholesterol, waist-
hip ratio, BMI, and fasting insulin, but significantly
correlated with triglycerides. 
There are some possible explanations for the lack of
association of RBP4 with indices of IR. First, HOMA-IR
may not be an ideal measurement of insulin sensitivity,
especially in subjects with impaired fasting glucose (IFG)
or impaired glucose tolerance (IGT).
20 Although HOMA-
IR has been shown to have a strong correlation with insulin
resistance in diabetic and non-diabetic subjects, the cor-
relation was not demonstrated in subjects with IFG or IGT.
Perhaps this may partially explain the lack of correlation
between RBP4 and HOMA IR in this study. However,
Stefan, et al.
21 has reported that RBP4 is associated with an
elevation of liver fat but not visceral fat in humans. Since
liver fat is associated with hepatic insulin sensitivity and
HOMA IR shows good correlation with hepatic insulin
sensitivity, there may be some other factors responsible for
the contradictory results. Perhaps the difference in results
may be attributed to a difference in ethnicity, degree of
obesity, and subset of the patients analyzed. This study
was performed on an Asian population with BMI and
HOMA indices that are relatively low compared to studies
performed on Caucasians. The study was also performed
on treated hypertensives with 38.6% of patients defined as
having metabolic syndrome, which may have influenced
the results. Second, the lack of association of RBP4 with
adiponectin, HMW adiponectin, BMI, waist-hip ratio, and
HDL cholesterol may be explained by the fact that RBP4
may not be associated with visceral and intramyocellular
fat. Since insulin increases the rate of depletion of vitamin
A from the liver, the association of RBP4 reported in pre-
vious studies may be the consequence of hepatic IR rather
than the cause.
22,23 Further studies are needed to clarify the
mechanism for the cross-sectional association of RBP4
with metabolic indices. 
Contrary to previous reports,
11,12 HMW adiponectin did
not demonstrate a superior predictive value for IR compared
to total adiponectin with the predictive value for IR being
slightly better for HMW adiponectin (AUC = 0.680) com-
pared to adiponectin (AUC = 0.648). HMW adiponectin
demonstrated a slightly stronger independent association
with the HOMA index and ApoB/ApoAI ratio compared
to total adiponectin. However, the HMW adiponectin/total
adiponectin ratio did not demonstrate a stronger associa-
tion with the HOMA index and metabolic indices. The
reason for the lack of stronger association of HMW adi-
ponectin with IR and metabolic indices is not clear. Several
studies have demonstrated the superiority of HMW adi-
ponectin compared to total adiponectin.
11,12,24 However, a
recent study by Blüher, et al.
25 demonstrated a lack of
superiority of HMW adiponectin over total adiponectin in
predicting metabolic variables at baseline and in response
to exercise. A possible explanation for the discrepancy may
be that the relationship between metabolic variables and
HMW adiponectin may be different in diabetics and non-
diabetics. Studies have shown that selective reduction of
posttranslational modification of the lysine residue of adi-
ponectin results in the lowering of HMW adiponectin in
diabetes, which increases in response to insulin sensiti-
zers.
25,26 The absence of diabetics in this study population
may account for the lack of superior association of HMW
adiponectin with metabolic variables.  
The limitations of this study need to be addressed. First,
the antihypertensive and lipid-lowering medications might
have partially influenced the results from the data. Statins
are known to increase the levels of heme oxygenase which
is regarded as the primary cellular defense mechanism
against increased levels of reactive oxygen species.
27  Heme
oxygenase and adiponectin levels move in conjunction
with animal models of obesity, hypertension, diabetes, and
metabolic syndrome.
28,29 It was possible that the level of
adipocytokines and metabolic parameters were influenced
by the medications, especially statins, but the proportions
of patients taking medications were not different between
the groups. Second was the difference in gender distribution
between the groups. To minimize the confusion, we
demonstrated and compared the level of adipocytokines
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according to gender in the two groups. Third, the study
sample only included Asians, and it is possible that results
from the present study may not be applicable to other
ethnic and racial groups. 
In conclusion, RBP4 was not associated with IR or
metabolic indices and the predictive value for IR was mini-
mal in hypertensive subjects. HMW adiponectin did not
have a superior predictive value for IR compared to adipo-
nectin. 
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